17 General introduction 27. Dickerson BC, Bakkour A, Salat DH, Feczko E, Pacheco J, Greve DN, et al. The cortical signature of Alzheimer’s disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cerebral cortex (New York, NY : 1991). 2009;19(3):497-510. 28. Rajan KB, Aggarwal NT, McAninch EA, Weuve J, Barnes LL, Wilson RS, et al. Remote Blood Biomarkers of Longitudinal Cognitive Outcomes in a Population Study. Ann Neurol. 2020;88(6):1065-76. 29. Verberk IMW, Laarhuis MB, van den Bosch KA, Ebenau JL, van Leeuwenstijn M, Prins ND, et al. Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. The Lancet Healthy Longevity. 2021. 30. Alexopoulos P, Kriett L, Haller B, Klupp E, Gray K, Grimmer T, et al. Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer’s disease. Alzheimer’s & dementia : the journal of the Alzheimer’s Association. 2014;10(6):684-9. 31. Jack JCR, Wiste HJ, Weigand SD, Knopman DS, Mielke MM, Vemuri P, et al. Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. Brain : a journal of neurology. 2015;138(12):3747-59. 32. Toledo JB, Weiner MW, Wolk DA, Da X, Chen K, Arnold SE, et al. Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. Acta neuropathologica communications. 2014;2:26. 33. Vos SJB, Gordon BA, Su Y, Visser PJ, Holtzman DM, Morris JC, et al. NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. Neurobiology of aging. 2016;44:1-8. 34. Ali JI, Smart CM, Gawryluk JR. Subjective Cognitive Decline and APOE ɛ4: A Systematic Review. Journal of Alzheimer’s Disease. 2018;65:303-20. 35. de Rojas I, Moreno-Grau S, Tesi N, Grenier-Boley B, Andrade V, Jansen IE, et al. Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores. Nature communications. 2021;12(1):3417. 36. Korte N, Nortley R, Attwell D. Cerebral blood flow decrease as an early pathological mechanism in Alzheimer’s disease. Acta Neuropathol. 2020;140(6):793-810. 37. Calsolaro V, Edison P. Neuroinflammation in Alzheimer’s disease: Current evidence and future directions. Alzheimer’s & dementia : the journal of the Alzheimer’s Association. 2016;12(6):719-32. 38. Golla SS, Verfaillie SC, Boellaard R, Adriaanse SM, Zwan MD, Schuit RC, et al. Quantification of [(18)F]florbetapir: A test-retest tracer kinetic modelling study. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 2019;39(11):2172-80. 39. Meyer PT, Hellwig S, Amtage F, Rottenburger C, Sahm U, Reuland P, et al. Dualbiomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2011;52(3):393-400. 1
RkJQdWJsaXNoZXIy MjY0ODMw